MedTrace Logo

Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure

NCT02653482 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 263

Last updated 2022-04-21

Study results available
· View outcomes & findings →

Summary

The primary purpose of this study is to evaluate the impact of dapagliflozin, as compared with placebo, on heart failure disease-specific biomarkers, symptoms, health status, and quality of life in patients with chronic heart failure with reduced systolic function.

Conditions

  • Chronic Heart Failure With Reduced Systolic Function

Interventions

DRUG

Dapagliflozin

DRUG

Dapagliflozin matching placebo

Sponsors & Collaborators

  • Saint Luke's Health System

    lead OTHER

Principal Investigators

  • Mikhail Kosiborod, MD · Saint Luke's Mid America Heart Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
119 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-03
Primary Completion
2019-06-28
Completion
2019-06-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02653482 on ClinicalTrials.gov